[1]蒋 峰,柳小芳,高艺文,等.解毒散结方联合化疗治疗晚期胃癌疗效及对患者血管内皮生长因子和受体的影响[J].陕西中医,2021,(5):582-585.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.009]
　JIANG Feng,LIU Xiaofang,GAO Yiwen,et al.Effect of Jiedu Sanjie recipe combined with chemotherapy on patients with advanced gastric cancer and the effect of serum VEGF and VEGFR-1[J].,2021,(5):582-585.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.009]
点击复制

解毒散结方联合化疗治疗晚期胃癌疗效及对患者血管内皮生长因子和受体的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年5期
页码:
582-585
栏目:
临床研究
出版日期:
2021-05-05

文章信息/Info

Title:
Effect of Jiedu Sanjie recipe combined with chemotherapy on patients with advanced gastric cancer and the effect of serum VEGF and VEGFR-1
作者:
蒋 峰1; 柳小芳1; 高艺文1; 孙晓虹1; 蒋士卿2
(1.滨州医学院烟台附属医院,山东 烟台 264100; 2.河南中医药大学第一附属医院,河南 郑州 450003)
Author(s):
JIANG Feng; LIU Xiaofang; GAO Yiwen; SUN Xiaohong; JIANG Shiqing
(Yantai Affiliated Hospital,Binzhou Medical University,Yantai 264100,China)
关键词:
晚期胃癌;  解毒散结方;  化疗;  血管内皮生长因子-A;  血管内皮生长因子-D;  血管内皮生长因子-1
Keywords:
Advanced gastric cancer;  Jiedu Sanjie recipe;  Chemotherapy;  Vascular endothelial growth factor-A;  Vascular Endothelial growth factor-D;  Vascular endothelial growth factor-1
分类号:
R 735.2
DOI:
DOI:10.3969/j.issn.1000-7369.2020.05.009
文献标志码:
A
摘要:
目的:探讨解毒散结方联合化疗对晚期胃癌患者疗效及对血清血管内皮生长因子-A(VEGF-A)、血管内皮生长因子-D(VEGF-D)、血管内皮生长因子受体-1(VEGFR-1)的影响。方法:选取102例晚期胃癌患者为研究对象,以随机数字表法分为对照组(替吉奥联合奥沙利铂化疗)和观察组(对照组基础上联合解毒散结方治疗),每组均为51例,两组均治疗12周。观察两组临床疗效、治疗前后中医症候评分、血清VEGF-A、VEGF-D、VEGFR-1水平以及治疗期间不良反应发生情况。结果:治疗12周后两组疗效等级分布比较差异显著(P<0.05),且观察组的总有效率高于对照组(P<0.05); 治疗12周后两组患者中医症候评分均降低(P<0.05),且观察组更低(P<0.05); 治疗12周后,两组血清VEGF-A、VEGFR-1水平均降低(P<0.05),两组血清VEGF-D水平均升高(P<0.05),且观察组血清VEGF-A、VEGFR-1水平更低(P<0.05),观察组血清VEGF-D水平更高(P<0.05); 两组不良反应发生率相近(P>0.05)。结论:解毒散结方联合替吉奥联合奥沙利铂化疗用于治疗脾胃虚弱、瘀毒蕴结证晚期胃癌患者能够改善临床症状及血管内皮生长因子水平,疗效显著。
Abstract:
Objective:To explore the curative effect of Jiedu Sanjie recipe combined with chemotherapy on patients with advanced gastric cancer and serum vascular endothelial growth factor-A(VEGF-A),vascular endothelial growth factor-D(VEGF-D),vascular endothelial growth factor receptor-1(VEGFR-1)impact.Methods:A total of 102 patients with advanced gastric cancer were selected as the research objects,they were divided into a control group(with Tiggio combined with oxaliplatin chemotherapy)and an observation group(on the basis of the treatment of the control group,combined with the treatment of Jiedu Sanjie decoction)according to the random number table,each group has 51 cases,and both groups were treated for 12 weeks.The clinical efficacy,Chinese medicine syndrome scores before and after treatment,serum VEGF-A,VEGF-D,and VEGFR-1 levels,and adverse reactions during the treatment period were observed.Results:After 12 weeks of treatment,there was a significant difference in the distribution of curative effect grades between the two groups(P<0.05),and the total effective rate of the observation group was higher than that of the control group(P<0.05); after 12 weeks of treatment,the scores of Chinese medicine symptoms in the two groups were reduced(P<0.05),and the observation group was lower(P<0.05); after 12 weeks of treatment,the serum VEGF-A and VEGFR-1 levels in the 2 groups decreased(P<0.05),and the serum VEGF-D levels in the 2 groups increased(P<0.05),and the observation group's serum VEGF-A and VEGFR-1 levels were lower(P<0.05),and the observation group's serum VEGF-D levels were higher(P<0.05); the incidence of adverse reactions in the two groups was similar(P>0.05).Conclusion:Jiedu Sanjie recipe combined with Tiggio and oxaliplatin chemotherapy can improve the clinical symptoms and vascular endothelial growth factor levels in patients with advanced gastric cancer,weakness of the spleen and stomach and stagnation of toxin,with significant curative effect.

参考文献/References:

[1] 千维娜,李 治,赵艳莉,等.益气健脾方辅助FOLFOX4化疗方案治疗胃癌术后脾胃虚弱证临床研究[J].中国中医药信息杂志,2020,27(5):12-17.
[2] 朱佳丽,周永宁,袁文臻,等.奥沙利铂联合替吉奥与奥沙利铂联合卡培他滨用于胃癌新辅助化疗后不良反应的比较[J].中国药物警戒,2020,17(1):17-22.
[3] 赵延军,黄 丽.胃癌中医辨证分型与TFF1、EGFR表达相关性研究[J].陕西中医,2018,39(5):565-567.
[4] 贾 茹,张影茹,邵诗芸,等.补肾解毒散结方调控JAK/STAT3信号通路抑制大肠癌侵袭转移的研究[J].中华中医药杂志,2020,35(3):1433-1436.
[5] 刘 伟,潘华峰,赵自明,等.健脾化瘀解毒方调控Wnt/β-catenin/GSK3β通路抑制胃癌前病变大鼠Lgr5+癌干细胞早期转移机制研究[J].中华中医药杂志,2017,32(5):1952-1956.
[6] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:361-362.
[7] 陈心足,胡建昆.胃癌规范化诊疗进展[J].华西医学,2018,33(4):379-384.
[8] 白日兰,崔久嵬.实体肿瘤免疫相关疗效评价标准的研究进展[J].中国肿瘤生物治疗杂志,2018,25(7):663-668.
[9] Boyd MR,Paull KD.Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen[J].Drug Development Research,2010,34(2):91-109.
[10] 朱广辉,李 杰,田启航,等.中医“胃气”理论指导下多角度治疗胃癌[J].辽宁中医药大学学报,2020,22(8):36-39.
[11] 窦建卫,杨小娟,李康乐,等.从气机升降探讨胃癌的病机治则[J].辽宁中医杂志,2020,47(2):76-77.
[12] 贾 茹,刘宁宁,季 青,等.补肾解毒散结方对大肠癌术后肿瘤转移及血管新生与金属蛋白酶表达的影响[J].上海中医药大学学报,2019,33(1):15-19.
[13] 许 玲,付艳丽,陈 健.解毒散结方对胃癌血管新生的影响及作用机制[J].时珍国医国药,2019,30(4):802-804.
[14] 马 蓉,张新爱,杨 洋,等.腺苷酸环化酶相关蛋白2、纤维连接蛋白1表达与胃癌病理类型及预后关系探讨[J].陕西医学杂志,2021,50(2):241-244.
[15] 李海英,白延斌.依托咪酯与丙泊酚对老年胃癌根治术患者皮质醇、醛固酮及丙二醛水平的影响[J].陕西医学杂志,2021,50(1):62-64.
[16] 张风芝,李岩岩,段晓萌,等.谷氨酰胺肠内营养在局部晚期胃癌治疗中的应用[J].西北药学杂志,2019,34(2):238-241.
[17] 王惠枫,沈 静,张甜甜.消癌平片联合常规化疗对胃癌患者血清TGF-α、VEGF水平的影响[J].海南医学,2020,31(2):181-183.
[18] 余 莹,胡 玲.中医药靶向干预Wnt/β-catenin信号通路治疗胃癌的研究进展[J].南京中医药大学学报,2019,35(4):471-476.
[19] 宋成鑫,葛信国,储 晶.养阴健脾散毒法辅助化疗治疗晚期胃癌临床研究[J].陕西中医,2020,41(11):1543-1547.
[20] 刘 鑫,张 锦,袁东红,等.复生康胶囊联合高强度聚焦超声消融术治疗胃癌肝转移临床研究[J].陕西中医,2020,41(2):164-167.

相似文献/References:

[1]李 雯 ,杜雅冰△,冯 堃,等.养正消积胶囊联合心理干预治疗胃癌晚期疗效及对患者生活质量、情绪的影响*[J].陕西中医,2019,(6):722.
　LI Wen,DU Yabing,FENG Wei,et al.Study on effects quality of life and emotion of Yangzheng Xiaoji capsule combined with psychological intervention on advanced gastric cancer[J].,2019,(5):722.
[2]刘包欣子,张 烨,张晶焱,等.健运清化方联合XELOX方案治疗晚期胃癌脾气虚弱证临床研究[J].陕西中医,2023,(10):1377.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.009]
　LIU Baoxinzi,ZHANG Ye,ZHANG Jingyan,et al.Jianyun Qinghua formula and XELOX regimen for the treatment of spleen weakness syndrome in advanced gastric cancer[J].,2023,(5):1377.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.009]

备注/Memo

备注/Memo:
基金项目:河南省科技攻关计划项目(082102310028)
更新日期/Last Update: 2021-05-10